Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
54.01
+0.62 (1.16%)
At close: Jul 22, 2026, 4:00 PM EDT
53.98
-0.03 (-0.06%)
Pre-market: Jul 23, 2026, 7:27 AM EDT
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $246.09M in the quarter ending March 31, 2026, with 86.98% growth. This brings the company's revenue in the last twelve months to $1.06B, up 47.53% year-over-year. In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth.
Revenue (ttm)
$1.06B
Revenue Growth
+47.53%
P/S Ratio
8.44
Revenue / Employee
$754,772
Employees
1,402
Market Cap
8.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| TG Therapeutics | 700.35M |
| Krystal Biotech | 417.30M |
| ImmunityBio | 140.98M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Crinetics Pharmaceuticals | 18.07M |
| Praxis Precision Medicines | 7.46M |
IONS News
- 1 day ago - Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim - TheFly
- 7 days ago - Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data - TheFly
- 7 days ago - Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research - TheFly
- 7 days ago - Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS - GlobeNewsWire
- 8 days ago - Ionis to hold second quarter 2026 financial results webcast - Business Wire
- 8 days ago - Ionis says Biogen presents Phase 2 CELIA data at AAIC - TheFly
- 8 days ago - Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease - Business Wire
- 9 days ago - Alnylam price target raised to $485 from $470 at H.C. Wainwright - TheFly